Pharmaceuticals & Biotechnology Editor | 03/10/2010
Given the changing epidemiology of disease due to Staphylococcus aureus (SA), including the emergence of drug-resistant organisms such as methicillin-resistant SA, investigators may wish to evaluatethe effects of antimicrobials in disease due to SA as well as in disease due to other organisms in the same trial. Here JH Powers and TR Fleming discuss issues that investigators should address in trial design, conduct, and analysisto evaluate overall effects or effects within subgroups according tocausative organisms.
Download PDF Attachment
RECOMMENDED
Upcoming Events
DigIT Pharma AI Commercial Excellence & Health 2025
September 1 - 3 2025
Palace Hotel Berlin, Germany
Register Now |
View Agenda |
Learn More
GenAI Life Science & Health 2025
September 1 - 3 2025
Berlin, Germany
Register Now |
View Agenda |
Learn More